281 related articles for article (PubMed ID: 26257198)
1. Pathophysiology of cutaneous lupus erythematosus.
Achtman JC; Werth VP
Arthritis Res Ther; 2015 Aug; 17(1):182. PubMed ID: 26257198
[TBL] [Abstract][Full Text] [Related]
2. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
Yu C; Chang C; Zhang J
J Autoimmun; 2013 Mar; 41():34-45. PubMed ID: 23380467
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
Scholtissek B; Zahn S; Maier J; Klaeschen S; Braegelmann C; Hoelzel M; Bieber T; Barchet W; Wenzel J
J Invest Dermatol; 2017 Jul; 137(7):1484-1492. PubMed ID: 28351661
[TBL] [Abstract][Full Text] [Related]
4. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.
Robinson ES; Werth VP
Cytokine; 2015 Jun; 73(2):326-34. PubMed ID: 25767072
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema.
Zhang YP; Wu J; Han YF; Shi ZR; Wang L
Autoimmun Rev; 2017 Jul; 16(7):735-742. PubMed ID: 28483542
[TBL] [Abstract][Full Text] [Related]
6. The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions.
Zhou X; Yan J; Lu Q; Zhou H; Fan L
Scand J Immunol; 2021 Jan; 93(1):e12933. PubMed ID: 32654170
[TBL] [Abstract][Full Text] [Related]
7. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
8. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus.
Wenzel J; Henze S; Wörenkämper E; Basner-Tschakarjan E; Sokolowska-Wojdylo M; Steitz J; Bieber T; Tüting T
J Invest Dermatol; 2005 Jun; 124(6):1241-8. PubMed ID: 15955100
[TBL] [Abstract][Full Text] [Related]
9. The classification and diagnosis of cutaneous lupus erythematosus.
Kuhn A; Landmann A
J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
[TBL] [Abstract][Full Text] [Related]
10. Ultraviolet radiation-induced cytokines promote mast cell accumulation and matrix metalloproteinase production: potential role in cutaneous lupus erythematosus.
Van Nguyen H; Di Girolamo N; Jackson N; Hampartzoumian T; Bullpitt P; Tedla N; Wakefield D
Scand J Rheumatol; 2011 May; 40(3):197-204. PubMed ID: 21247265
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of cutaneous lupus erythematosus--novel aspects.
Kuhn A; Krammer PH; Kolb-Bachofen V
Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii14-6. PubMed ID: 16987823
[TBL] [Abstract][Full Text] [Related]
12. Role of neutrophils in cutaneous lupus erythematosus.
Yamamoto T
J Dermatol; 2024 Feb; 51(2):180-184. PubMed ID: 38009863
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray.
Toberer F; Sykora J; Göttel D; Hartschuh W; Werchau S; Enk A; Joos S; Krammer PH; Kuhn A
Exp Dermatol; 2013 Oct; 22(10):656-9. PubMed ID: 24079735
[TBL] [Abstract][Full Text] [Related]
14. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
15. NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.
Vorwerk G; Zahn S; Bieber T; Wenzel J
Exp Dermatol; 2021 Jun; 30(6):847-852. PubMed ID: 33687107
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in cutaneous lupus.
Maz MP; Martens JWS; Hannoudi A; Reddy AL; Hile GA; Kahlenberg JM
J Autoimmun; 2022 Oct; 132():102865. PubMed ID: 35858957
[TBL] [Abstract][Full Text] [Related]
17. Current Knowledge of the Molecular Pathogenesis of Cutaneous Lupus Erythematosus.
Miyagawa F
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769633
[TBL] [Abstract][Full Text] [Related]
18. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
[TBL] [Abstract][Full Text] [Related]
19. A multicenter photoprovocation study to identify potential biomarkers by global peptide profiling in cutaneous lupus erythematosus.
Calderon C; Zucht HD; Kuhn A; Wozniacka A; Szepietowski JC; Nyberg F; Weichenthal M; Piantone A; Budde P
Lupus; 2015 Nov; 24(13):1406-20. PubMed ID: 26206719
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous lupus erythematosus: The impact of self-amplifying innate and adaptive immune responses and future prospects of targeted therapies.
Fetter T; Wenzel J
Exp Dermatol; 2020 Nov; 29(11):1123-1132. PubMed ID: 32633821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
